High-risk COVID outpatients least likely to receive monoclonal antibodiesNonhospitalized COVID-19 patients at highest risk for severe outcomes are often the least likely to receive monoclonal antibodies (mAbs), finds a study of more than 1.9 million Medicare beneficiaries published late last week in JAMA.A team led by a Harvard Medical School researcher examined a sample of outpatient, emergency department, and laboratory insurance claims for fee-for-service Medicare beneficiaries who received a new diagnosis of COVID-19 or had a confirmed exposure from November 2020 to August 2021.
mAbs were first available for use in COVID-19 patients in November 2020.Among the 1,902,914 participants, 7.2% received mAbs.
Patients with fewer underlying illnesses were more likely than those with more conditions to receive the treatment (23.2% with 0 chronic conditions vs 6.3%, 6.0%, and 4.7% with 1 to 3, 4 or 5, and 6 or more chronic conditions, respectively; adjusted odds ratio [aOR], 7.43 for 0 vs 6 or more).Black patients were less likely than their White peers to be given mAb (6.2% vs 7.4%; aOR, 0.77), as were those who were also enrolled in Medicaid (4.6% vs 8.1%; aOR, 0.74).
Participants 85 years and older were 42% more likely to receiving mAbs than those 65 to 74.Administration of mAb also varied widely by US region, with Rhode Island (24.9%) and Louisiana (21.2%) administering the most, while Alaska (1.1%) and Washington (0.7%) had the lowest rates.